Related Experiment Videos
[Antitumor immunology in the year 2000 and the new immunosuppressive therapy]
1División de Hematología-Oncología, Universidad de California, Los Angeles, USA.
Medicina Clinica
|June 10, 2000
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 study.
Annals of oncology : official journal of the European Society for Medical Oncology·2024
Antitumor activity of ipilimumab or BRAF ± MEK inhibition after pembrolizumab treatment in patients with advanced melanoma: analysis from KEYNOTE-006.
Annals of oncology : official journal of the European Society for Medical Oncology·2021
Biochar application and summer temperatures reduce N2O and enhance CH4 emissions in a Mediterranean agroecosystem: Role of biologically-induced anoxic microsites.
The Science of the total environment·2019
Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001.
Annals of oncology : official journal of the European Society for Medical Oncology·2019
Tularemia: a re-emerging zoonosis.
Medicina clinica·2026
Complex regional pain syndrome and amputation.
Medicina clinica·2026
Corrected Version: IL-12 p40 Monomer is Different from Other IL-12 Family Members to Selectively Inhibit IL-12Rβ1 Internalization and Suppress EAE.
Journal of clinical & experimental immunology·2026